BRAF V600E — biomarker · CancerIndex

Biomarker · Gene alteration

BRAF V600E

BRAF codon 600 point mutation p.V600E detected by sequencing, PCR or mutation-specific immunohistochemistry; used as a predictive marker for BRAF/MEK inhibitor therapy across melanoma, thyroid, colorectal, lung and other cancers.

CI-BIO-00000018BRAF graph →NCIt C98342 Tumor-agnostic · 4 approval rows

Also calledp.V600E · BRAF V600E-mutant · c.1799T>A

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug + indication textRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Trametinib US FDA · May 29, 2013 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (24)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	37	31	6	—	1 / 21 / 6 / 8 / 1
Melanoma	31	29	2	—	0 / 19 / 2 / 10 / 0
Thyroid Gland Papillary Carcinoma	12	3	8

Derived

Drugs with predictive evidence (29)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	45	36	9	A	34 / 9	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +12
DabrafenibSmall Molecule	22	19	3	A	18 / 4	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
TrametinibSmall Molecule	20	19	1	A	18 / 0	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
CetuximabMonoclonal Antibody	12	6	6	A	6 / 5	Malignant Colorectal Neoplasm
PanitumumabMonoclonal Antibody	9	6	3	B	4 / 2	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	6	3	3	B	3 / 3	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	4	3	1	B	1 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
CobimetinibSmall Molecule	3	3	—	B	3 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
OxaliplatinSmall Molecule	2	—	2	B	0 / 2	Malignant Colorectal Neoplasm
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
SorafenibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
TovorafenibSmall Molecule	1	1	—	A	1 / 0	Childhood Low Grade Glioma
MEK Inhibitor RO4987655	1	—	1	B	—	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (92)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 92 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF V600E45
Vemurafenib	Childhood Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
Irinotecan + Panitumumab + VemurafenibCombination	Cholangiocarcinoma
BRAF K601E + BRAF V600E1
Cobimetinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID11670 This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC) PMID 36409971 · Klute et al., 2022 · Open in CIViC	civic
BRAF Amplification + BRAF V600E1
Selumetinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	E	Supports Resistance	4	accepted	EID92 COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC) PMID 21098728 · Corcoran et al., 2010 · Open in CIViC	civic
ARAF S490T + BRAF V600EBRAF ARAF1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID1905 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic
BRAF V600E + GNAS R201CBRAF GNAS1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID1906 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (364)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved	Mar 16, 2023	openfda
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved

1 record matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (472)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 247 recruiting · 84 active phase 3 · 2,295 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 51–100 of 472 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04166409	A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma	recruiting	Phase 3	170	National Cancer Institute (NCI)NIH	3	Sep 11, 2026	clinicaltrials
NCT04485013	TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	active not recruiting	Phase 1	240	Tizona Therapeutics, IncINDUSTRY	1	Sep 11, 2026	clinicaltrials
NCT04923126	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	recruiting	Phase 1 / Phase 2	132	St. Jude Children's Research HospitalOTHER	1	Sep 11, 2026	clinicaltrials
NCT04929223	A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	recruiting	Phase 1	542	Hoffmann-La RocheINDUSTRY	11	Sep 11, 2026	clinicaltrials
NCT05845450	Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)	recruiting	Phase 2	197	Gruppo Oncologico del Nord-OvestOTHER	1	Sep 11, 2026	clinicaltrials
NCT05985954	Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy	recruiting	Phase 1	27	M.D. Anderson Cancer CenterOTHER	1	Sep 11, 2026	clinicaltrials
NCT06840002	A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer	recruiting	Phase 1 / Phase 2	150	Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY	1	Sep 11, 2026	clinicaltrials
NCT07247110	A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)	recruiting	Phase 1	250	Merck Sharp & Dohme LLCINDUSTRY	7	Sep 11, 2026	clinicaltrials
NCT07381764	ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"(ROMANCE - GOIM)	recruiting	Phase 2	150	Gruppo Oncologico Italia MeridionaleOTHER	1	Sep 11, 2026	clinicaltrials
NCT07743164	A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)	not yet recruiting	Phase 3	646	Merck Sharp & Dohme LLCINDUSTRY	0	Sep 11, 2026	clinicaltrials
NCT07746141	A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations	recruiting	Phase 1	100	BeOne MedicinesINDUSTRY	1	Sep 11, 2026	clinicaltrials
NCT01364051	Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies	active not recruiting	Phase 1	19	National Cancer Institute (NCI)NIH	1	Sep 10, 2026	clinicaltrials
NCT04302025	A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)(NAUTIKA1)	recruiting	Phase 2	99	Genentech, Inc.INDUSTRY	1	Sep 10, 2026	clinicaltrials
NCT04931342	A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors(BOUQUET)	active not recruiting	Phase 2	176	Hoffmann-La RocheINDUSTRY	13	Sep 10, 2026	clinicaltrials
NCT07775287	Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)	recruiting	Phase 3	600	GenmabINDUSTRY	1	Sep 10, 2026	clinicaltrials
NCT03040973	Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone	active not recruiting	Phase 2	29	Novartis PharmaceuticalsINDUSTRY	11	Sep 9, 2026	clinicaltrials
NCT06037980	CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY)	recruiting	Phase 2 / Phase 3	300	Gruppo Oncologico del Nord-OvestOTHER	1	Sep 9, 2026	clinicaltrials
NCT06561360	A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)	recruiting	Phase 2	86	Memorial Sloan Kettering Cancer CenterOTHER	1	Sep 9, 2026	clinicaltrials
NCT06578559	Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC(BRICKET)	active not recruiting	Phase 2	16	Gruppo Oncologico del Nord-OvestOTHER	1	Sep 9, 2026	clinicaltrials
NCT06625775	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	recruiting	Phase 1	392	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY	6	Sep 9, 2026	clinicaltrials
NCT06696768	Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer	recruiting	Phase 1	24	National Cancer Institute (NCI)NIH	1	Sep 9, 2026	clinicaltrials
NCT07225270	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy(RAINFOL-04)	recruiting	Phase 3	544	GenmabINDUSTRY	3	Sep 9, 2026	clinicaltrials
NCT07549412	A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)	recruiting	Phase 3	1,020	EMD Serono Research & Development Institute, Inc.INDUSTRY	16	Sep 9, 2026	clinicaltrials
NCT07797283	Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1(MAESTRA 3)	not yet recruiting	Phase 3	590	Incyte CorporationINDUSTRY	0	Sep 9, 2026	clinicaltrials
NCT02997228	Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study	active not recruiting	Phase 3	120	National Cancer Institute (NCI)NIH	1	Sep 8, 2026	clinicaltrials
NCT03006172	To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer	active not recruiting	Phase 1	200	Genentech, Inc.INDUSTRY	5	Sep 8, 2026	clinicaltrials
NCT03715933	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	recruiting	Phase 1	411	Inhibrx Biosciences, IncINDUSTRY	6	Sep 8, 2026	clinicaltrials
NCT07228832	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer(HARMONi-GI3)	recruiting	Phase 3	600	Summit TherapeuticsINDUSTRY	14	Sep 8, 2026	clinicaltrials
NCT02642042	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	active not recruiting	Phase 2	60	National Cancer Institute (NCI)NIH	1	Sep 4, 2026	clinicaltrials
NCT06400472	A Study of Sofe-M in Participants With Selected Advanced Solid Tumors	recruiting	Phase 1	575	Eli Lilly and CompanyINDUSTRY	7	Sep 4, 2026	clinicaltrials
NCT03178552	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST)	active not recruiting	Phase 2 / Phase 3	1,000	Hoffmann-La RocheINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT04657991	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma	active not recruiting	Phase 3	257	PfizerINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT06252649	Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301)	recruiting	Phase 3	450	AmgenINDUSTRY	35	Sep 3, 2026	clinicaltrials
NCT06271837	A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors	active not recruiting	Phase 2	127	AstraZenecaINDUSTRY	1	Sep 3, 2026	clinicaltrials
NCT06824467	A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)	recruiting	Phase 3	770	Merck Sharp & Dohme LLCINDUSTRY	29	Sep 3, 2026	clinicaltrials
NCT07110246	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas(PNOC037)	recruiting	Phase 2	96	University of California, San FranciscoOTHER	1	Sep 3, 2026	clinicaltrials
NCT07441707	A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours	active not recruiting	Phase 1	6	IpsenINDUSTRY	1	Sep 3, 2026	clinicaltrials
NCT07801027	A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)	not yet recruiting	Phase 4	150	Merck Sharp & Dohme LLCINDUSTRY	0	Sep 3, 2026	clinicaltrials
NCT07801352	CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer	active not recruiting	Phase 2	15	Shanghai Changzheng HospitalOTHER	1	Sep 3, 2026	clinicaltrials
NCT05862285	A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX)	recruiting	Phase 3	100	Hoffmann-La RocheINDUSTRY	15	Sep 2, 2026	clinicaltrials
NCT07216105	FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors	recruiting	Phase 1	119	Fate TherapeuticsINDUSTRY	1	Sep 2, 2026	clinicaltrials
NCT07252739	KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)	recruiting	Phase 2	140	Merck Sharp & Dohme LLCINDUSTRY	13	Sep 2, 2026	clinicaltrials
NCT07283939	Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays	recruiting	N/A	420	Alliance for Clinical Trials in OncologyOTHER	3	Sep 2, 2026	clinicaltrials
NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	Phase 1	30	City of Hope Medical CenterOTHER	1	Sep 2, 2026	clinicaltrials
NCT03600701	Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer	active not recruiting	Phase 2	53	National Cancer Institute (NCI)NIH	1	Sep 1, 2026	clinicaltrials
NCT04557956	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	active not recruiting	Phase 1 / Phase 2	16	National Cancer Institute (NCI)NIH	1	Sep 1, 2026	clinicaltrials
NCT05355701	A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.	active not recruiting	Phase 1	103	PfizerINDUSTRY	3	Sep 1, 2026	clinicaltrials
NCT05627635	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	20	City of Hope Medical CenterOTHER	1	Sep 1, 2026	clinicaltrials
NCT06576037	Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin	recruiting	Phase 1	128	M.D. Anderson Cancer CenterOTHER	1	Sep 1, 2026	clinicaltrials
NCT06730750	A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	active not recruiting	Phase 1 / Phase 2	360	Bristol-Myers SquibbINDUSTRY	3	Sep 1, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Bevacizumab

EU EMA

—

VEGZELMA in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. VEGZELMA in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. VEGZELMA in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with VEGZELMA in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. VEGZELMA, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (NSCLC) other than predominantly squamous cell histology. VEGZELMA, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). VEGZELMA, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. VEGZELMA, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). VEGZELMA, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor–targeted agents. VEGZELMA in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1). VEGZELMA, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

approved

Aug 17, 2022

ema

Bevacizumab

EU EMA

—

Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1). Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

approved

Apr 21, 2021

ema

Bevacizumab

EU EMA

—

Oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Oyavas in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. Oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see Section 5.1). Oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

approved

Mar 26, 2021

ema

Bevacizumab

EU EMA

—

Alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. Alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Alymsys in combination with capecitabine. Alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. Alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

approved

Mar 26, 2021

ema

Bevacizumab

EU EMA

—

Onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Onbevzi in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

withdrawn

Jan 11, 2021

ema

Bevacizumab

EU EMA

—

Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Equidacent in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

withdrawn

Sep 24, 2020

ema

Bevacizumab

EU EMA

—

Aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1 of the SmPC. Aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Aybintio in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1 of the SmPC. Aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1 of the SmPC). Aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1 of the SmPC). Aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see section 5.1 of the SmPC). Aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1 of the SmPC).

approved

Aug 19, 2020

ema

Bevacizumab

EU EMA

—

Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

approved

Jan 15, 2018

ema

Bevacizumab

EU EMA

—

Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine. For further information as to HER2 status. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

approved

Jan 12, 2005

ema

Approval rows flagged tumor-agnostic (4)

Associated cancers (24)

Drugs with predictive evidence (29)

Predictive evidence items (92)

Approvals mentioning the linked drugs (364)

Active trials (472)

Linked publications (85)